| Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma R Chen, PL Zinzani, MA Fanale, P Armand, NA Johnson, P Brice, ... Journal of Clinical Oncology 35 (19), 2125-2132, 2017 | 1013 | 2017 |
| Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087 R Chen, PL Zinzani, HJ Lee, P Armand, NA Johnson, P Brice, J Radford, ... Blood, The Journal of the American Society of Hematology 134 (14), 1144-1153, 2019 | 309 | 2019 |
| Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial N Kalakonda, M Maerevoet, F Cavallo, G Follows, A Goy, JSP Vermaat, ... The Lancet Haematology 7 (7), e511-e522, 2020 | 274 | 2020 |
| Targeted temperature management in critical care: a report and recommendations from five professional societies ME Nunnally, R Jaeschke, GJ Bellingan, J Lacroix, B Mourvillier, ... Critical care medicine 39 (5), 1113-1125, 2011 | 228 | 2011 |
| Clinical approach to lymphadenopathy P GA Seminars in oncology 20, 570-582, 1993 | 226 | 1993 |
| Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma MC Kyrtsonis, TP Vassilakopoulos, N Kafasi, S Sachanas, T Tzenou, ... British journal of haematology 137 (3), 240-243, 2007 | 203 | 2007 |
| Senescence and senotherapeutics: a new field in cancer therapy V Myrianthopoulos, K Evangelou, PVS Vasileiou, T Cooks, ... Pharmacology & therapeutics 193, 31-49, 2019 | 177 | 2019 |
| CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin’s disease: associations with presenting features and clinical outcome GZ Rassidakis, LJ Medeiros, S Viviani, V Bonfante, GP Nadali, ... Journal of Clinical Oncology 20 (5), 1278-1287, 2002 | 148 | 2002 |
| BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens GZ Rassidakis, LJ Medeiros, TP Vassilakopoulos, S Viviani, V Bonfante, ... Blood, The Journal of the American Society of Hematology 100 (12), 3935-3941, 2002 | 140 | 2002 |
| Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care TP Vassilakopoulos, GA Pangalis, A Katsigiannis, SG Papageorgiou, ... The oncologist 17 (2), 239-249, 2012 | 138 | 2012 |
| B-chronic lymphocytic leukemia, small lymphocytic lymphoma, and lymphoplasmacytic lymphoma, including Waldenström's macroglobulinemia: a clinical, morphologic, and biologic … GA Pangalis, MK Angelopoulou, TP Vassilakopoulos, MP Siakantaris, ... Seminars in hematology 36 (2), 104-114, 1999 | 138 | 1999 |
| A prospective, cohort, multicentre study of candidaemia in hospitalized adult patients with haematological malignancies MN Gamaletsou, TJ Walsh, T Zaoutis, M Pagoni, M Kotsopoulou, ... Clinical Microbiology and Infection 20 (1), O50-O57, 2014 | 121 | 2014 |
| A novel immunological assay for hepcidin quantification in human serum V Koliaraki, M Marinou, TP Vassilakopoulos, E Vavourakis, E Tsochatzis, ... PloS one 4 (2), e4581, 2009 | 120 | 2009 |
| Rituximab monotherapy is highly effective in splenic marginal zone lymphoma C Kalpadakis, GA Pangalis, MN Dimopoulou, TP Vassilakopoulos, ... Hematological oncology 25 (3), 127-131, 2007 | 118 | 2007 |
| Expression of Epstein-Barr virus latent membrane protein-1 in Hodgkin and Reed-Sternberg cells of classical Hodgkin’s lymphoma: associations with presenting features, serum … M Herling, GZ Rassidakis, LJ Medeiros, TP Vassilakopoulos, KO Kliche, ... Clinical cancer research 9 (6), 2114-2120, 2003 | 102 | 2003 |
| Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy C Kalpadakis, GA Pangalis, MK Angelopoulou, S Sachanas, ... The Oncologist 18 (2), 190-197, 2013 | 101 | 2013 |
| Waldenström's macroglobulinemia: clinical course and prognostic factors in 60 patients: Experience from a single hematology unit MC Kyrtsonis, T Vassilakopoulos, M Angelopoulou, M Siakantaris, ... Annals of hematology 80, 722-727, 2001 | 100 | 2001 |
| Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma L Mansouri, D Noerenberg, E Young, E Mylonas, M Abdulla, M Frick, ... Blood, The Journal of the American Society of Hematology 128 (23), 2666-2670, 2016 | 98 | 2016 |
| Clonal B-cell lymphocytosis exhibiting immunophenotypic features consistent with a marginal-zone origin: is this a distinct entity? A Xochelli, C Kalpadakis, A Gardiner, P Baliakas, TP Vassilakopoulos, ... Blood, The Journal of the American Society of Hematology 123 (8), 1199-1206, 2014 | 95 | 2014 |
| Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders: A review GA Pangalis, MN Dimopoulou, MK Angelopoulou, C Tsekouras, ... Medical Oncology 18, 99-107, 2001 | 91 | 2001 |
MARIA ANGELOPOULOUASSOCIATE PROFESSOR IN HEMATOLOGY, NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS在 MED.UOA.GR 的电子邮件经过验证
